Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Revenue (2016 - 2025)

Historic Revenue for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $15.2 million.

  • Aytu Biopharma's Revenue fell 651.01% to $15.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.6 million, marking a year-over-year increase of 199.79%. This contributed to the annual value of $66.4 million for FY2025, which is 183.94% up from last year.
  • Latest data reveals that Aytu Biopharma reported Revenue of $15.2 million as of Q4 2025, which was down 651.01% from $13.9 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Revenue high stood at $30.7 million for Q2 2023, and its period low was $13.5 million during Q1 2021.
  • Over the past 5 years, Aytu Biopharma's median Revenue value was $18.6 million (recorded in 2023), while the average stood at $20.1 million.
  • As far as peak fluctuations go, Aytu Biopharma's Revenue soared by 7947.79% in 2022, and later crashed by 5251.53% in 2024.
  • Quarter analysis of 5 years shows Aytu Biopharma's Revenue stood at $23.1 million in 2021, then increased by 13.64% to $26.3 million in 2022, then decreased by 28.66% to $18.7 million in 2023, then decreased by 13.48% to $16.2 million in 2024, then decreased by 6.51% to $15.2 million in 2025.
  • Its Revenue stands at $15.2 million for Q4 2025, versus $13.9 million for Q3 2025 and $15.1 million for Q2 2025.